Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 100

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 100
---
 and uncertainties in our ability to maintain key business relationships. |

As a result, if we enter into
collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions,
which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction or license, we may not achieve
the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with a suitable collaborator
on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug or diagnostics technology candidate,
reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense.

If we fail to enter into collaborations,
we may seek to fund and undertake development or commercialization activities on our own, but we may not have sufficient funds or expertise
to undertake the necessary development and commercialization activities. In such a case, we may not be able to further develop our drug
and diagnostics technology candidates or bring them to market and generate product sales revenue, which would harm our business prospects,
financial condition and results of operations.

Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.

We are exposed to the risk
of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors.
Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA and
other similar non-U.S. regulatory authorities; provide true, complete and accurate information to the FDA and other similar non-U.S. regulatory
authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States
and similar non-U.S. fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities
to us. If we obtain the FDA approval for any of our drug and diagnostics technology candidates and begin commercializing those drugs in
the United States, our potential exposure under U.S. laws will increase significantly and our costs associated with compliance
with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators
of our sponsored researches and research patients and our use of information obtained in the